D&D Pharmatech Sets 2027 Launch for Liver Fibrosis Therapy
Mental Health

D&D Pharmatech Sets 2027 Launch for Liver Fibrosis Therapy

By Marcus Reid · · 2 min read

Targeting the Cells That Build Scar Tissue

Korean biotech D&D Pharmatech has scheduled the start of Phase 1 clinical trials for TLY012, a new drug candidate targeting liver fibrosis. The company confirmed that enrollment will begin in the first half of 2027. This follows a mixed result for its earlier Parkinson’s drug, NLY01.

The company’s previous lead candidate, NLY01, missed its primary endpoint in a Phase 2 trial for Parkinson’s disease. However, post-hoc analysis revealed that patients under 60 showed measurable improvement. Researchers at Johns Hopkins noted this age-specific response. D&D Pharmatech is now pivoting its pipeline focus toward liver health with TLY012.

Why Did the Company Keep a Drug That Missed Its Main Goal?

TLY012 works by targeting the specific cells responsible for building scar tissue in the liver. Liver fibrosis progresses when these cells overproduce collagen, stiffening the organ. The drug aims to interrupt this process before it becomes irreversible cirrhosis. Clinical data from preclinical models showed significant reduction in fibrosis markers. The Phase 1 trial will assess safety and basic efficacy in human volunteers.

Not every drug that fails its primary endpoint gets discarded. D&D Pharmatech kept NLY01 because the younger patient subgroup responded well. This suggests the drug may work best in a specific demographic. The company plans to refine the trial design for TLY012 to avoid similar issues. They will define clear inclusion criteria based on age and disease stage.

When does the TLY012 Phase 1 trial start? The trial is scheduled to begin in the first half of 2027. Enrollment will target patients with early-stage liver fibrosis.

Frequently Asked Questions

What makes TLY012 different from existing liver drugs? It specifically targets the cells that produce scar tissue. This mechanism differs from current therapies that manage symptoms rather than the root cause.

Did NLY01 fail completely? No. While it missed its primary endpoint overall, patients under 60 showed benefit. The company is using this insight to shape the new trial design.

Leave a comment

Every comment is read before it goes live. You will see it published once approved. You can send at most 2 comments per hour.